Compare FRMM & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRMM | NRXS |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 78.9M |
| IPO Year | 2017 | 2023 |
| Metric | FRMM | NRXS |
|---|---|---|
| Price | $4.51 | $7.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 511.2K | 177.3K |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | $183.55 | $172.91 |
| Revenue Next Year | $166.48 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $1.76 | $2.20 |
| 52 Week High | $5.87 | $9.33 |
| Indicator | FRMM | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 44.43 |
| Support Level | $4.25 | $6.80 |
| Resistance Level | $5.55 | $8.03 |
| Average True Range (ATR) | 0.54 | 0.63 |
| MACD | -0.09 | -0.16 |
| Stochastic Oscillator | 46.12 | 8.97 |
Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).